Overview

A Study of LY3009104(Baricitinib) for Healthy Subjects

Status:
Completed
Trial end date:
2011-04-01
Target enrollment:
Participant gender:
Summary
To evaluate the safety and tolerability of LY3009104 when given orally as single and multiple doses in Japanese healthy subjects.
Phase:
Phase 1
Details
Lead Sponsor:
Eli Lilly and Company